The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

NCT03819790 · Completed

Last updated 2026-05-28

This clinical trial is testing the effect of Soliqua on blood sugar control in South Asian adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 119 people

Who can join Ages 18–80 · all sexes

Timeline Started 2018-10 · est. completion 2019-11

Where 3 sites · Canada

What this study is testing ClinicalTrials.gov NCT03819790 ↗

Description as written by the study sponsor.

The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).

Treatments tested

Basal insulin glargine and lixisenatide Drug

Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
Basal insulin Basaglar/Lantus + gliclazide MR Drug

basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
Metformin Drug

Patients can be administered with most tolerant dose of metformin

Main thing measured	Time in range at week 13
Sponsor	LMC Diabetes & Endocrinology Ltd.
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03819790 ↗